Cargando…

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation

Circulating plasma cells at diagnosis, prior to auto-transplant and at relapse have a negative impact on survival in multiple myeloma. However, the impact of kinetics of circulating plasma cells along the course of illness has not been defined. We have analyzed 247 newly diagnosed multiple myeloma p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Rajshekhar, Muchtar, Eli, Kumar, Shaji K., Jevremovic, Dragan, Buadi, Francis K., Dingli, David, Dispenzieri, Angela, Hayman, Suzanne R., Hogan, William J., Kapoor, Prashant, Lacy, Martha Q., Leung, Nelson, Gertz, Morie A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541877/ https://www.ncbi.nlm.nih.gov/pubmed/28473618 http://dx.doi.org/10.3324/haematol.2017.166629

Ejemplares similares

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
por: Chakraborty, R, et al.
Publicado: (2016)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
por: Al Saleh, Abdullah S., et al.
Publicado: (2022)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
por: Pang, Li, et al.
Publicado: (2021)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Importance of FISH genetics in light chain amyloidosis
por: Gertz, Morie A., et al.
Publicado: (2017)

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
por: Hwa, Yi L., et al.
Publicado: (2016)

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2020)

Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome
por: Muchtar, Eli, et al.
Publicado: (2022)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
por: Abdallah, N., et al.
Publicado: (2022)

Conditional survival in multiple myeloma and impact of prognostic factors over time
por: Abdallah, Nadine H., et al.
Publicado: (2023)

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
por: Ravi, Praful, et al.
Publicado: (2018)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

Kidney Transplant Outcomes of Patients With Multiple Myeloma
por: Heybeli, Cihan, et al.
Publicado: (2022)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ib2ssekphg4035144k37ikirpm